NCT01273402撤回1 期
Pretargeted Radioimmunotherapy of Colorectal Cancer: A Phase I Study to Determine Dose-limiting Toxicity and Maximum Tolerated Dose of an Anti-CEACAM5 bsMAb-pretargeted 90Y-hapten-peptide
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- Determine the number of adverse events
研究概览
简要总结
This study is being done to select an appropriate TF2 bsMAb dose suitable for pretargeting the 111In/90Y-labeled hapten-peptide (IMP-288). Eligible patients will receive a fixed dose of 90Y-IMP-288 4 days after the TF2 antibody injection. Two different dose levels of TF2 will be studied in the first part.
Once an appropriate TF2 dose is selected based on information learned from the first 2 dose levels, patients will be enrolled onto several different increasing dose levels of 90Y-IMP-288.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients, >18 years of age.
- •documented histologic or cytologic diagnosis of metastatic (Stage IV) colorectal cancer.
- •must have at least one confirmed and measurable tumor lesion (a confirmed tumor site is one in which either biopsy-proven evidence of disease or progressive growth has been radiographically observed).
- •Patients must have failed standard therapy or for whom no standard therapy exists.
- •Patients must have a Karnofsky performance status of ≥ 70% (or equivalent ECOG 0-1) and an expected survival of ≥ 3 months.
- •Patients who previously received a chimeric, CDR-grafted (humanized), or human IgG will be eligible provided pre-study evaluations demonstrate no significant anti-antibody reactivity with TF
- •Hematologic parameters: WBC counts must be ≥ 3000/mm3, granulocytes
- •1500/mm3, and platelets ≥ 100,000/m
- •Non-hematologic parameters: Patients without liver metastases must have bilirubin ≤ 1.5 institutional upper limit of normal (IULN), whereas bilirubin in patients with known liver metastases must be <2.5-times the IULN. AST/ALT must not be >2.5 times IULN.
- •At least 2 weeks beyond corticosteroids, except low doses (i.e., 20 mg/day of prednisone or equivalent) to treat nausea or other illness such as rheumatoid arthritis.
- •Patients able to understand and give written informed consent. Informed consent must be obtained prior to baseline studies for enrollment purposes.
排除标准
- •Women who are pregnant or lactating. Women of childbearing potential and fertile men will be informed as to the potential risk of procreation while participating in this trial and will be advised that they must use effective contraception during and for a period of 3 months.
- •Patients with plasma CEA >1000 ng/mL or lesions exceeding 10 cm in diameter.
- •Patients with severe anorexia or other gastrointestinal-related symptomatology (e.g., nausea, vomiting).
- •Patients with known HIV or hepatitis B or C.
- •Patients with an active second primary malignancy at the time of study entry, with the exception of carcinoma in situ of the cervix.
- •Patients with known metastatic disease to the central nervous system.
- •Patients with evidence of bone marrow metastases. Screening only required for patients with suspicion of metastases. Patients with ≥ 25% bone marrow involvement are excluded.
- •Patients who are, in the opinion of the investigator, unable to comply with the protocol requirements.
- •Institutionalized subjects (e.g., prisons, psychiatric facilities).
- •Known history of active coronary artery disease, unstable angina, myocardial infarction, or congestive heart failure present within 6 months or cardiac arrhythmia requiring anti-arrhythmia therapy.
- •Known autoimmune disease or presence of autoimmune phenomena (except rheumatoid arthritis requiring only low dose maintenance corticosteroids); or infection requiring intravenous antibiotic use within 1 week.
- •Known history of active COPD, or other moderate-to-severe respiratory illness present within 6 months.
- •Patients who are diabetic and/or have high blood pressure are at a higher risk for developing late-stage renal failure. While these patients will not be specifically excluded, physician-investigators must carefully discuss the associated late risks to these patients.
- •Patients must be at least 4 weeks beyond prior chemotherapy, surgery, radiotherapy to an index lesion, or experimental therapy (i.e., drugs, biologicals, procedures) and meet all eligibility criteria.
- •Patients who received a treatment containing a nitrosourea compound will not be enrolled for at least 6 weeks after the end of that treatment.
研究组 & 干预措施
TF2 and IMP288
Experimental
TF2 will be administered at least 4 days before the radiolabeled IMP-288.
干预措施: TF2/IMP288 (Drug)
结局指标
主要结局
Determine the number of adverse events
时间窗: Safety will be measured routinely during the 3 weeks of administration and afterwards during follow-up for up to 5 years
Safety will be assessed by determing the number of participants with Adverse Events as a Measure of Safety and Tolerability.
次要结局
- Efficacy will be evaluating using CT scans and possibly PET imaging.(Efficacy will be measured at 4 and 8 weeks after treatment and every 3 months for up to 2 years.)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's LymphomaLymphomaNCT00073931Fred Hutchinson Cancer Center25
已完成
2 期
Phase II Two-step Radioimmunotherapy Clinical Study in Medullary Thyroid CarcinomaThyroid NeoplasmsNCT00467506Nantes University Hospital
已完成
1 期
Radioimmunotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast CancerBreast CancerNCT00004085Garden State Cancer Center at the Center for Molecular Medicine and Immunology15
已完成
1 期
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal CancerAdenocarcinoma of the ColonAdenocarcinoma of the RectumRecurrent Colon CancerRecurrent Rectal CancerStage IV Colon CancerStage IV Rectal CancerNCT00023933National Cancer Institute (NCI)15
撤回
2 期
Consolidative Radiotherapy for Colorectal Cancer Liver Metastases Receiving Surgery or Radiofrequency AblationRadiotherapyLiver MetastasesColorectal CancerNCT03135652Wuhan Union Hospital, China